Deslorelin (acetate)
(Synonyms: D-Trp6-Pro9-des-Gly10-GnRH ethylamide, pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt) 目录号 : GC49143
A peptide agonist of GnRH
Cas No.:1642579-30-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Deslorelin is a peptide agonist of gonadotropin-releasing hormone (GnRH).1 It binds to the GnRH receptor (GnRHR) with a Ki value of 0.1 nM. Deslorelin decreases testicular volume, semen volume, sperm motility, and total sperm count, as well as increases the percentage of abnormal sperm, in dogs when administered via a subcutaneous implant at doses of 3, 6, and 12 mg/kg.2 It decreases disease severity and plasma levels of estradiol, 17-hydroxyprogesterone, and androstenedione in ferrets with adrenocortical disease (ACD) when administered at doses ranging from 3 to 4.41 mg/kg per implant.3 Deslorelin (4.7 mg/implant per animal) suppresses ovulation and estrus in cats.4 Formulations containing deslorelin have been used in the management of ACD in ferrets and ovulation regulation and artificial insemination in horses.
1.Nederpelt, I., Georgi, V., Schiele, F., et al.Characterization of 12 GnRH peptide agonists - a kinetic perspectiveBr. J. Pharmacol.173(1)128-141(2016) 2.Junaidi, A., Williamson, P.E., Martin, G.B., et al.Dose-response studies for pituitary and testicular function in male dogs treated with the GnRH superagonist, deslorelinReprod. Domest. Anim.44(5)725-734(2009) 3.Wagner, R.A., PichÉ, C.A., JÖchle, W., et al.Clinical and endocrine responses to treatment with deslorelin acetate implants in ferrets with adrenocortical diseaseAm. J. Vet. Res.66(5)910-914(2005) 4.Ackermann, C.L., Volpato, R., Destro, F.C., et al.Ovarian activity reversibility after the use of deslorelin acetate as a short-term contraceptive in domestic queensTheriogenology78(4)817-822(2012)
| Cas No. | 1642579-30-3 | SDF | |
| 别名 | D-Trp6-Pro9-des-Gly10-GnRH ethylamide, pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt | ||
| Canonical SMILES | OC(C=C1)=CC=C1C[C@H](NC([C@H](CO)NC([C@@H](NC([C@@H](NC([C@H]2NC(CC2)=O)=O)CC3=CN=CN3)=O)CC4=CNC5=CC=CC=C45)=O)=O)C(N[C@@H](C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N6[C@@H](CCC6)C(NCC)=O)=O)=O)=O)CC7=CNC8=CC=CC=C78)=O.CC(O)=O | ||
| 分子式 | C64H83N17O12·XC2H4O2 | 分子量 | 1282.5 |
| 溶解度 | DMF: 5 mg/ml,DMSO: 5 mg/ml,Ethanol: 10 mg/ml | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.7797 mL | 3.8986 mL | 7.7973 mL |
| 5 mM | 0.1559 mL | 0.7797 mL | 1.5595 mL |
| 10 mM | 0.078 mL | 0.3899 mL | 0.7797 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet